Our research shows the transformative effect that alemtuzumab can have for people with MS.
Patients who continue to show disease activity while on their initial therapy are especially difficult to treat.
Now, we have shown that alemtuzumab works where first-line drugs have already failed.
It not only reduces the chances of disability associated with MS but may even result in long-term clinical improvements.
More top news
The daughter of a missing RSPCA inspector has paid tribute to her "amazing" dad - saying she was coming to terms with him not coming home.
Energy company E.ON and charity Age UK have temporarily suspended a branded energy deal following criticism of the deal.
A fresh inquest will be opened into the death of toddler Poppi Worthington next month.